Response to treatment in patients with chronic hepatitis C genotype and drug sovodak newly diagnosed patients with previous treatment failure
- Conditions
- Chronic Hepatitis C.Chronic viral hepatitis C
- Registration Number
- IRCT201702016388N7
- Lead Sponsor
- Vice Chancellor for Research of Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
People with HCV genotype HCV RNA in a headline above or positive? People who have detectable HCV RNA titers after previous treatment failure and relapse patients.
Exclusion criteria: People who sovodak therapy to stop for any reason? People infected with virus (HIV) concurrently? There is no reason other than HCV patients with chronic hepatitis? People with hepatitis B concurrently? People who have undergone liver transplantation recently? People who have low life expectancy? There is no assurance that the cut intravenous drug users inject drugs? Patients who received Amiodarone in the last 6 months? Women who are pregnant or plan to become pregnant or are breastfeeding? Those who have allergies to Lactose (sovodak with Lactose).
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hepatitis C RNA. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Test.
- Secondary Outcome Measures
Name Time Method iver Echogenicity. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: paraclinical tests.;Albumin. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Test.;Portal vein diameter. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Sonography.;Splenic vein diameter. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Sonography.;Spleen size. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Sonography.;INR. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Test.